Biography and Research Information
OverviewAI-generated summary
Yifan Zhang's research investigates the intricate relationship between the gut microbiome and various health outcomes. Their work includes studies on how gut microbiota metabolism disturbances are associated with postoperative atrial fibrillation after coronary artery bypass grafting, and alterations in fecal microbiota of methamphetamine users with poor sleep quality during abstinence. Zhang has also explored the role of the gut microbiome and immune-related adverse events in gastrointestinal cancer patients treated with immune checkpoint inhibitors, and the potential of fecal microbiota transplantation to enhance immunotherapy sensitivity in refractory gastrointestinal cancer patients.
Further research extends to the genetic regulation of plant traits, such as the PpyMYB144 transcription factor's role in pear fruit skin russeting. Additionally, Zhang has examined the application of large language models to enhance pharmacogenomic data accessibility and drug safety. Their scholarship metrics include an h-index of 6, with 12 total publications and 172 total citations. Key collaborators include Leihong Wu and Joshua Xu from the National Center for Toxicological Research.
Metrics
- h-index: 6
- Publications: 12
- Citations: 180
Selected Publications
-
Enhancing pharmacogenomic data accessibility and drug safety with large language models: a case study with Llama3.1 (2024)
-
Deep oncopanel sequencing reveals fixation time- and within block position-dependent quality degradation in FFPE processed samples (2021)
Collaboration Network
Top Collaborators
- Correlation of the gut microbiome and immune-related adverse events in gastrointestinal cancer patients treated with immune checkpoint inhibitors
- Fecal microbiota transplantation promotes immunotherapy sensitivity in refractory gastrointestinal cancer patients: open label, single-arm, single center, phase 1 study
- Correlation of the gut microbiome and immune-related adverse events in gastrointestinal cancer patients treated with immune checkpoint inhibitors
- Fecal microbiota transplantation promotes immunotherapy sensitivity in refractory gastrointestinal cancer patients: open label, single-arm, single center, phase 1 study
- Correlation of the gut microbiome and immune-related adverse events in gastrointestinal cancer patients treated with immune checkpoint inhibitors
- Fecal microbiota transplantation promotes immunotherapy sensitivity in refractory gastrointestinal cancer patients: open label, single-arm, single center, phase 1 study
- Correlation of the gut microbiome and immune-related adverse events in gastrointestinal cancer patients treated with immune checkpoint inhibitors
- Fecal microbiota transplantation promotes immunotherapy sensitivity in refractory gastrointestinal cancer patients: open label, single-arm, single center, phase 1 study
- Correlation of the gut microbiome and immune-related adverse events in gastrointestinal cancer patients treated with immune checkpoint inhibitors
- Fecal microbiota transplantation promotes immunotherapy sensitivity in refractory gastrointestinal cancer patients: open label, single-arm, single center, phase 1 study
- Correlation of the gut microbiome and immune-related adverse events in gastrointestinal cancer patients treated with immune checkpoint inhibitors
- Fecal microbiota transplantation promotes immunotherapy sensitivity in refractory gastrointestinal cancer patients: open label, single-arm, single center, phase 1 study
- Table of Contents
- Table of Contents
- Table of Contents
- Table of Contents
- Table of Contents
- Table of Contents
- Table of Contents
- Table of Contents
- Table of Contents
Similar Researchers
Based on overlapping research topics